{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:18:24Z","timestamp":1789384704033,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["15373, 2014"],"award-info":[{"award-number":["15373, 2014"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003980","name":"Istituto Toscano Tumori","doi-asserted-by":"publisher","award":["2013"],"award-info":[{"award-number":["2013"]}],"id":[{"id":"10.13039\/501100003980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.cytogfr.2017.07.003","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T21:45:17Z","timestamp":1499895917000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences"],"prefix":"10.1016","volume":"36","author":[{"given":"Luana","family":"Calabr\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Luca","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armida","family":"D\u2019Incecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2017.07.003_bib0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0010","first-page":"497","article-title":"Standardizing surgical treatment in malignant pleural mesothelioma","volume":"1","author":"Rice","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients","volume":"117","author":"Sugarbaker","year":"1999","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0020","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"MARS trialists, Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasur","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0025","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0035","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial","volume":"384","author":"Rintoul","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0040","unstructured":"National Institutes of Health. MARS 2: A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in patients with malignant pleural mesothelioma (MARS2). NCT02040272. http:\/\/www.clinicaltrials.gov."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0045","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/ejcts\/ezv398","article-title":"Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma","volume":"49","author":"Kostron","year":"2016","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.radonc.2011.09.025","article-title":"Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series","volume":"101","author":"Tonoli","year":"2011","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0055","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2015.06.029","article-title":"Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignantpleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0065","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol."},{"issue":"November (5)","key":"10.1016\/j.cytogfr.2017.07.003_bib0070","article-title":"Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years","author":"Friedberg","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0075","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"de Perrot","year":"2016","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0080","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0085","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0090","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0095","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second-line therapy in malignant pleural mesothelioma","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0115","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0120","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J. Pathol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0125","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/13543784.2012.681641","article-title":"Anti-angiogenic therapies for malignant pleural mesothelioma","volume":"21","author":"Ceresoli","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0130","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0135","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0140","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0145","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French cooperative thoracic intergroup (IFCT), bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0150","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.2147\/OTT.S78805","article-title":"Profile of nintedanib in the treatment of solid tumors: the evidence to date","volume":"8","author":"Awasthi","year":"2015","journal-title":"Onco Target Ther."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8506","article-title":"Mature overall survival results from the LUME-Meso study of nintedanib\u2009+\u2009pemetrexed\/cisplatin vs placebo\u2009+\u2009PEM\/CIS in chemo-na\u00efve patients with malignant pleural mesothelioma","volume":"35","author":"Nowak","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0160","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1158\/0008-5472.CAN-12-3932","article-title":"Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer","volume":"73","author":"Aerts","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0165","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0170","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0175","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0180","doi-asserted-by":"crossref","first-page":"e106742","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coph.2014.06.007","article-title":"Immunomodulation in cancer","volume":"17","author":"Hegmans","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0190","article-title":"Checkpoint blockade in lung cancer and mesothelioma","volume":"2","author":"Lievense","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second- or third-line treatment in relapsed malignant mesothelioma: a phase 2b, randomised, double-blind, placebo-controlled study (DETERMINE)","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0200","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0205","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function","volume":"10","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0210","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjc.6605814","article-title":"Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma","volume":"103","author":"Veltman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0215","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-16-0309","article-title":"Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy","author":"Dammeijer","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0220","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","article-title":"Mesothelin-targeted agents in clinical trials and in preclinical development","volume":"11","author":"Kelly","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0225","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0230","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0235","unstructured":"National Institutes of Health. Study of the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in subjects with unresectable malignant pleural mesothelioma (ARTEMIS). NCT02357147. http:\/\/www.clinicaltrials.gov."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0240","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.2509","article-title":"Phase I study of anti-mesothelin antibody-drug conjugate anetumab ravtansine","volume":"34","author":"Blumenschein","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0245","unstructured":"National Institutes of Health. Phase II anetumab ravtansine as second line treatment for malignant pleural mesothelioma. NCT02610140. http:\/\/www.clinicaltrials.gov."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0250","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.seminoncol.2010.09.006","article-title":"Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications","volume":"37","author":"Calabr\u00f2","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0255","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0260","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00262-014-1609-9","article-title":"CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic\/target therapy?","volume":"64","author":"Calabr\u00f2","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0270","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0275","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0280","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0285","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0290","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0295","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0300","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8557","article-title":"Biomarkers of pembrolizumab activity in mesothelioma: results from a phase II trial","volume":"35","author":"Kindler","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0305","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"A Phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research biopsies","volume":"12","author":"Quispel-Janssen","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0310","unstructured":"National Institutes of Health. Checkpoint blockade for inhibition of relapsed mesothelioma (CONFIRM): a phase III double-blind, placebo controlled trial to evaluate the efficacy of nivolumab in relapsed mesothelioma. NCT03063450. http:\/\/www.clinicaltrials.gov."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0315","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0320","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(17)30191-2","article-title":"Immune checkpoint inhibitors in malignant pleural mesothelioma","volume":"18","author":"Ceresoli","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0325","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0330","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0335","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0340","first-page":"1","article-title":"Immunotherapy for malignant mesothelioma: reality check","volume":"6","author":"Thapa","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0345","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0350","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0355","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8558","article-title":"Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study","volume":"35","author":"Calabro","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2017.07.003_bib0360","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA8507","article-title":"French cooperative thoracic intergroup (IFCT), second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial","volume":"35","author":"Scherpereel","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610117301168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610117301168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,29]],"date-time":"2019-09-29T20:39:50Z","timestamp":1569789590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610117301168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":72,"alternative-id":["S1359610117301168"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2017.07.003","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2017.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}